ES2783624T3 - Dímeros de benzodiacepina, conjugados de los mismos y métodos de preparación y uso - Google Patents
Dímeros de benzodiacepina, conjugados de los mismos y métodos de preparación y uso Download PDFInfo
- Publication number
- ES2783624T3 ES2783624T3 ES16703196T ES16703196T ES2783624T3 ES 2783624 T3 ES2783624 T3 ES 2783624T3 ES 16703196 T ES16703196 T ES 16703196T ES 16703196 T ES16703196 T ES 16703196T ES 2783624 T3 ES2783624 T3 ES 2783624T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- mmol
- independently
- substituted
- dimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*N(C(*)C=C1)C1=O Chemical compound C*N(C(*)C=C1)C1=O 0.000 description 5
- FHNMAOLQZHUPIJ-UHFFFAOYSA-N CC(C)C(ON(C(CC1)=O)C1=O)=O Chemical compound CC(C)C(ON(C(CC1)=O)C1=O)=O FHNMAOLQZHUPIJ-UHFFFAOYSA-N 0.000 description 1
- UNBMPKNTYKDYCG-UHFFFAOYSA-N CC(C)CC(C)N Chemical compound CC(C)CC(C)N UNBMPKNTYKDYCG-UHFFFAOYSA-N 0.000 description 1
- WFZAHVGKERHSTC-OMYKBPHGSA-N CC(C)NC1C=CC(C(CC2C=Nc(c3c4)cc(OCCCOc(cc(c5c6)N=C[C@H](Cc7ccccc7C7)N7C5=O)c6OC)c4OC)=CN2C3=O)=CC1 Chemical compound CC(C)NC1C=CC(C(CC2C=Nc(c3c4)cc(OCCCOc(cc(c5c6)N=C[C@H](Cc7ccccc7C7)N7C5=O)c6OC)c4OC)=CN2C3=O)=CC1 WFZAHVGKERHSTC-OMYKBPHGSA-N 0.000 description 1
- LKGBWAFXCLXYRL-UHFFFAOYSA-N CC(Cc1ccccc1-1)c(cccc2)c2-c(nn2)c-1[n]2I Chemical compound CC(Cc1ccccc1-1)c(cccc2)c2-c(nn2)c-1[n]2I LKGBWAFXCLXYRL-UHFFFAOYSA-N 0.000 description 1
- YADIXAWTPSMTRY-UHFFFAOYSA-N CCc(cc1)ccc1N1CCN(C)CC1 Chemical compound CCc(cc1)ccc1N1CCN(C)CC1 YADIXAWTPSMTRY-UHFFFAOYSA-N 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N Cc(cc1)ccc1N Chemical compound Cc(cc1)ccc1N RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N Cc(cccc1)c1N Chemical compound Cc(cccc1)c1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N Cc1cccc(N)c1 Chemical compound Cc1cccc(N)c1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103157P | 2015-01-14 | 2015-01-14 | |
| US201562215928P | 2015-09-09 | 2015-09-09 | |
| PCT/US2016/013136 WO2016115191A1 (en) | 2015-01-14 | 2016-01-13 | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2783624T3 true ES2783624T3 (es) | 2020-09-17 |
Family
ID=55305072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16703196T Active ES2783624T3 (es) | 2015-01-14 | 2016-01-13 | Dímeros de benzodiacepina, conjugados de los mismos y métodos de preparación y uso |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9527871B2 (enExample) |
| EP (1) | EP3245213B1 (enExample) |
| JP (1) | JP6498773B2 (enExample) |
| KR (1) | KR20170102980A (enExample) |
| CN (1) | CN107428780B (enExample) |
| AU (1) | AU2016206798A1 (enExample) |
| BR (1) | BR112017014599A2 (enExample) |
| CA (1) | CA2973354A1 (enExample) |
| CL (1) | CL2017001824A1 (enExample) |
| CO (1) | CO2017008078A2 (enExample) |
| EA (1) | EA201791550A1 (enExample) |
| ES (1) | ES2783624T3 (enExample) |
| IL (1) | IL253402A0 (enExample) |
| MX (1) | MX2017009145A (enExample) |
| PE (1) | PE20171184A1 (enExample) |
| SG (1) | SG11201705646XA (enExample) |
| TW (1) | TW201632531A (enExample) |
| WO (1) | WO2016115191A1 (enExample) |
| ZA (1) | ZA201704738B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107231804B (zh) * | 2015-01-14 | 2019-11-26 | 百时美施贵宝公司 | 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法 |
| US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| WO2018053552A2 (en) * | 2016-09-19 | 2018-03-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| CN110049780A (zh) * | 2016-10-10 | 2019-07-23 | 塞勒兰特治疗公司 | 异喹啉并苯并二氮杂卓(iqb)-1(氯甲基)-2,3-二氢-1h-苯并[e]吲哚(cbi)二聚体 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| HRP20230002T1 (hr) * | 2017-01-25 | 2023-02-17 | Immunogen, Inc. | Postupci pripreme citotoksičnih derivata benzodiazepina |
| WO2018195243A1 (en) * | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| WO2019036433A2 (en) | 2017-08-16 | 2019-02-21 | Bristol-Myers Squibb Company | ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION |
| GB201714115D0 (en) | 2017-09-04 | 2017-10-18 | Femtogenix Ltd | Cytotoxic agents |
| CA3177215C (en) | 2017-09-29 | 2026-06-09 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| CN112166115A (zh) * | 2018-05-29 | 2021-01-01 | 尹图赛利有限公司 | 新型苯二氮杂*衍生物及其用途 |
| EP3873912B1 (en) | 2018-10-31 | 2026-03-25 | Intocell, Inc. | Fused heterocyclic benzodiazepine derivatives and uses thereof |
| CA3119956A1 (en) | 2018-11-14 | 2020-05-22 | Daiichi Sankyo Company, Limited | Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate |
| DK3886914T3 (da) | 2018-11-30 | 2023-07-03 | Bristol Myers Squibb Co | Antistof omfattende en glutaminholdig letkæde-c-terminal forlængelse, konjugater deraf og fremgangsmåder samt anvendelser |
| WO2020123425A2 (en) | 2018-12-12 | 2020-06-18 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| BR112021017616A2 (pt) | 2019-03-25 | 2021-11-09 | Daiichi Sankyo Co Ltd | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina |
| EP3950061A4 (en) | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
| EP3949988A4 (en) | 2019-03-27 | 2022-11-16 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND A PARP INHIBITOR |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| US20240377413A1 (en) | 2019-09-16 | 2024-11-14 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CN117425501A (zh) | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗体-吡咯并苯二氮䓬衍生物缀合物 |
| CN113372245B (zh) * | 2021-06-17 | 2023-01-13 | 仪征市海帆化工有限公司 | 一种n-苯甲酰基-o,o-对甲苯磺酰基-二乙醇胺的合成方法 |
| WO2023037237A1 (en) * | 2021-09-09 | 2023-03-16 | Wavelength Enterprises Ltd | Process for the preparation of remimazolam |
| EP4410830A4 (en) * | 2021-09-30 | 2026-07-08 | Ajinomoto Kk | CONJUGATE OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR ITS SALT, DERIVATIVE OF ANTIBODY AND COMPOUND OR ITS SALTS FOR USE IN THE PRODUCTION OF A CONJUGATE OR ITS SALT |
| WO2023100829A1 (ja) | 2021-11-30 | 2023-06-08 | 第一三共株式会社 | プロテアーゼ分解性マスク抗体 |
| AU2023218678A1 (en) | 2022-02-09 | 2024-08-01 | Daiichi Sankyo Company, Limited | Environmentally responsive masked antibody and use thereof |
| WO2025214466A1 (en) * | 2024-04-12 | 2025-10-16 | BeiGene Guangzhou Biologics Manufacturing Co., Ltd. | Targeted pyrrolobenzodiazapine conjugates |
| WO2026096695A1 (en) * | 2024-10-31 | 2026-05-07 | Bristol-Myers Squibb Company | Anti-fucosyl-gm1 antibody drug conjugates |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2260570T3 (es) | 1998-08-27 | 2006-11-01 | Spirogen Limited | Pirrolobenziodiazepinas dimericas. |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| ES2398975T3 (es) | 2004-03-01 | 2013-03-25 | Spirogen Sàrl | Derivados de 11-hidroxi-5H-pirrolo[2,1-c][1,4]benzodiazepin-5-ona como intermedios clave para la preparación de pirrolobenzodiazepinas sustituidas en C2 |
| EP1723152B1 (en) | 2004-03-09 | 2015-02-11 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| ES2338696T3 (es) | 2005-04-21 | 2010-05-11 | Spirogen Limited | Pirrolobenzodiazepinas. |
| EP1934261B1 (en) | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Human monoclonal antibodies to cd70 |
| EA017491B1 (ru) | 2005-12-08 | 2012-12-28 | Медарекс, Инк. | Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител |
| DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
| AU2008275985B2 (en) | 2007-07-17 | 2013-09-19 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
| PT2019104E (pt) | 2007-07-19 | 2013-12-03 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica |
| HRP20150074T1 (hr) | 2007-10-01 | 2015-03-13 | Bristol-Myers Squibb Company | Humana antitijela koja se vežu za mezotelin i njihove uporabe |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CA3014224C (en) * | 2009-02-05 | 2022-05-24 | Immunogen, Inc. | Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| SI2675480T1 (sl) * | 2011-02-15 | 2019-05-31 | Immunogen, Inc. | Metode priprave konjugatov |
| US9399641B2 (en) | 2011-09-20 | 2016-07-26 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
| CA2850264C (en) | 2011-10-14 | 2019-11-05 | Medimmune Limited | Pyrrolobenzodiazepines |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| JP6104257B2 (ja) | 2011-10-14 | 2017-03-29 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンおよびそのコンジュゲート |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| HK1211208A1 (zh) | 2012-08-22 | 2016-05-20 | Immunogen, Inc. | 細胞毒性苯並二氮呯衍生物 |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| PT2906248T (pt) | 2012-10-12 | 2019-03-04 | Medimmune Ltd | Pirrolobenzodiazepinas e conjugados das mesmas |
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| ES2687439T3 (es) | 2013-03-13 | 2018-10-25 | Medimmune Limited | Pirrolobenzodiazepinas y conjugados de las mismas |
| MX363787B (es) | 2013-03-13 | 2019-04-03 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de los mismos. |
| KR102066318B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
-
2016
- 2016-01-13 TW TW105100987A patent/TW201632531A/zh unknown
- 2016-01-13 BR BR112017014599A patent/BR112017014599A2/pt not_active Application Discontinuation
- 2016-01-13 JP JP2017537227A patent/JP6498773B2/ja not_active Expired - Fee Related
- 2016-01-13 KR KR1020177022244A patent/KR20170102980A/ko not_active Ceased
- 2016-01-13 EP EP16703196.2A patent/EP3245213B1/en active Active
- 2016-01-13 US US14/994,296 patent/US9527871B2/en active Active
- 2016-01-13 EA EA201791550A patent/EA201791550A1/ru unknown
- 2016-01-13 CA CA2973354A patent/CA2973354A1/en not_active Abandoned
- 2016-01-13 PE PE2017001216A patent/PE20171184A1/es unknown
- 2016-01-13 WO PCT/US2016/013136 patent/WO2016115191A1/en not_active Ceased
- 2016-01-13 CN CN201680006151.5A patent/CN107428780B/zh not_active Expired - Fee Related
- 2016-01-13 AU AU2016206798A patent/AU2016206798A1/en not_active Abandoned
- 2016-01-13 MX MX2017009145A patent/MX2017009145A/es unknown
- 2016-01-13 SG SG11201705646XA patent/SG11201705646XA/en unknown
- 2016-01-13 ES ES16703196T patent/ES2783624T3/es active Active
- 2016-11-15 US US15/351,843 patent/US9676794B2/en active Active
-
2017
- 2017-05-05 US US15/587,715 patent/US9822144B2/en active Active
- 2017-07-10 IL IL253402A patent/IL253402A0/en unknown
- 2017-07-13 CL CL2017001824A patent/CL2017001824A1/es unknown
- 2017-07-13 ZA ZA2017/04738A patent/ZA201704738B/en unknown
- 2017-08-10 CO CONC2017/0008078A patent/CO2017008078A2/es unknown
- 2017-10-17 US US15/785,675 patent/US10112975B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107428780A (zh) | 2017-12-01 |
| PE20171184A1 (es) | 2017-08-22 |
| EP3245213B1 (en) | 2020-03-04 |
| JP6498773B2 (ja) | 2019-04-10 |
| CO2017008078A2 (es) | 2017-11-10 |
| MX2017009145A (es) | 2017-11-22 |
| US20160200742A1 (en) | 2016-07-14 |
| KR20170102980A (ko) | 2017-09-12 |
| CL2017001824A1 (es) | 2018-02-09 |
| US9822144B2 (en) | 2017-11-21 |
| CN107428780B (zh) | 2020-09-04 |
| TW201632531A (zh) | 2016-09-16 |
| US20180079781A1 (en) | 2018-03-22 |
| US20170073357A1 (en) | 2017-03-16 |
| WO2016115191A1 (en) | 2016-07-21 |
| AU2016206798A1 (en) | 2017-08-31 |
| ZA201704738B (en) | 2019-02-27 |
| JP2018503639A (ja) | 2018-02-08 |
| US9527871B2 (en) | 2016-12-27 |
| US10112975B2 (en) | 2018-10-30 |
| US9676794B2 (en) | 2017-06-13 |
| IL253402A0 (en) | 2017-09-28 |
| CA2973354A1 (en) | 2016-07-21 |
| EA201791550A1 (ru) | 2017-11-30 |
| US20170233436A1 (en) | 2017-08-17 |
| SG11201705646XA (en) | 2017-08-30 |
| EP3245213A1 (en) | 2017-11-22 |
| BR112017014599A2 (pt) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10112975B2 (en) | Benzodiazepine dimers, conjugates thereof, and methods of making and using | |
| ES2747386T3 (es) | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso | |
| ES2615268T3 (es) | Compuestos de enediino, conjugados de los mismos y usos y métodos para ello | |
| ES2895369T3 (es) | Agonistas del receptor tipo toll 7 (TLR7) que tienen un resto tricíclico, conjugados de estos y métodos y usos de estos | |
| US9688694B2 (en) | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | |
| ES2902179T3 (es) | Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso |